FORMULATION ARTICLES
-
![antibody molecules-GettyImages-2165626333]( "A Smarter Switch: Reprogramming CIP Systems With Nanobodies Unlocks New Control Over Cell Signaling")
A Smarter Switch: Reprogramming CIP Systems With Nanobodies Unlocks New Control Over Cell SignalingEngineered nanobodies reprogram CIP systems, enabling precise, reversible control of protein interactions, signaling pathways, and gene expression without redesigning core chemistry.
-
![Molecular structure for medical, technology, chemistry, science-GettyImages-2228457760]( "Can Making mRNA More \"Rigid\" Unlock The Next Leap In RNA Medicines?")
Can Making mRNA More "Rigid" Unlock The Next Leap In RNA Medicines?Can stabilizing mRNA structure unlock better performance? New strategies aim to “rigidify” mRNA, improving translation, stability, and manufacturability while reducing variability across conditions.
-
![Genetic engineering, Genetic testing, pharmacy, Regenerative medicine-GettyImages-1459917354]( "Rethinking The Oligonucleotide Backbone: A New Approach To RNA Therapeutic Design")
Rethinking The Oligonucleotide Backbone: A New Approach To RNA Therapeutic DesignBackbone engineering reframes RNA design, enabling programmable charge, uptake, and delivery — transforming oligonucleotides from fixed structures into tunable, multifunctional therapeutic systems.
-
![DNA, medical research-GettyImages-919410014]( "AI Foundation Models For RNA Biology")
AI Foundation Models For RNA BiologyAI foundation models are transforming RNA biology by learning sequence–structure–function relationships, enabling accurate predictions, scalable discovery, and deeper insight into RNA regulation and design.
-
![GettyImages-1410189348]( "Nanosystems And Rare Diseases: Opportunities And Limitations")
Nanosystems And Rare Diseases: Opportunities And LimitationsNanosystems offer unique capabilities, enabling researchers to design precise, versatile delivery systems that address key challenges in rare diseases.
-
![cell biology, biochemistry, cellular signaling, cell integrity-GettyImages-2196575143]( "The Potency Chains Of Events For mRNA/LNP Therapeutics")
The Potency Chains Of Events For mRNA/LNP TherapeuticsPotency in mRNA/LNP therapies depends on two chains: manufacturing/cold chain integrity and complex in vivo delivery. Breakdowns at any step — from stability to translation — can limit efficacy and safety.
FORMULATION VIDEOS
Camp4’s Satya Kuchimanchi highlights where he has seen the most growth in the oligo supply chain over the past few years, as well as which industry trends have been driving these shifts.
Develop RNA-lipid nanoparticles (LNPs) in under 10 seconds for drug discovery and early preclinical development. The NanoAssemblr®️ Spark™ instrument enables rapid µL formulations to conserve limited and expensive ingredients with minimal waste.
A connected development pathway supports smoother scale-up and greater consistency for LNP-based therapeutics. Explore how integrated expertise across key stages helps teams accelerate progress.
The clinical promise of mRNA therapeutics and vaccines is clear, but compared to monoclonal antibodies or viral vectors, their novelty also brings new challenges to the manufacturing process.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-1298788278 drug manufacturing]( "Improving U.S. Drug Supply Stability Through Continuous Nanoparticle Processing")
Learn about a continuous manufacturing platform designed to help overcome challenges in domestic pharmaceutical production, including scale-up barriers and production variability.
-
![Genomic sequencing, molecular biology, and genetic data analysis-GettyImages-2153790378]( "The Paradigm Shift: From Scale-Up To Scale-Out In Genetic Medicine")
The shift from "scale-up" to "scale-out" in genetic medicine enhances production speed, revolutionizing pharmaceutical manufacturing and accelerating life-saving therapies for global patient populations.
-
![Scientists In Laboratory GettyImages-1140779754]( "Defining A Process For Your Unique mRNA")
Define a process for your unique mRNA with this interactive guide to pDNA, mRNA, and LNP. Overcome challenges with solutions that can help you develop a next-generation production strategy.
-
![mRNA iStock-1295693748]( "Transfection Solutions For Highly Reliable And Effective Gene Silencing With siRNA And Co.")
We discuss the process of transfection and highlight two highly effective vectors for both in vitro and in vivo gene therapy applications.
-
![MRNA Technology-GettyImages-1366661187]( "Developing An mRNA-Encoded Antibody Platform To Accelerate Therapies To Clinic")
In this paper, we present the foundation of an mRNA-LNP platform for encoding and expressing therapeutic antibodies in vivo, eliminating the need for costly and time-consuming manufacturing.
-
![RNA abbreviation of ribonucleic acid-GettyImages-1453953422]( "Navigating Challenges In Progressing Breakthrough RNA Therapeutics")
RNA therapeutics hold immense promise for precision treatment, but their development faces challenges. A CDMO with adaptable platforms and flexible timelines can help reduce time and costs.
-
![GettyImages-525440891-lab-research-development]( "Avoiding The Pitfalls Of LNPs And Complex Formulations")
Explore the necessary components of a smooth tech transfer for LNP-based drugs, including the variables that impact LNP formulation and the outsourcing strategies needed to avoid common pitfalls.
